{{Infobox drug
| drug_name         = 
| IUPAC_name        = (4a''S'',5a''R'',12a''S'')-3,10,12,12a-Tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydronaphthacen-2-carboxamide
| image             = Incyclinide skeletal.svg
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = Metastat (proposed)
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A / B            / C / D / X / N -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_NZ = <!--Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = Abandoned?
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action =
| excretion         = 
<!-- Identifiers -->
| CAS_number        = 15866-90-7
| ATCvet            = 
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 54678924
| DrugBank          = 
| ChemSpiderID      = 28530521
| UNII              = 21G64WZQ4I
| ChEMBL            = 2104970
| KEGG              = D04519
<!-- Chemical data -->
| C=19 | H=17 | N=1 | O=7
| smiles = c1cc2c(c(c1)O)C(=O)C3=C([C@]4([C@@H](C[C@@H]3C2)CC(=C(C4=O)C(=O)N)O)O)O
| StdInChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21-22,24,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1
| StdInChIKey = ZXFCRFYULUUSDW-OWXODZSWSA-N
}}

'''Incyclinide''' (proposed trade name '''Metastat''') is a chemically modified [[tetracycline antibiotic]] that was investigated in clinical trials for the treatment of [[rosacea]],<ref name="Reuters" /> various tumours, allergic and inflammatory diseases and a number of other conditions. The drug has no antibiotic properties.<ref name="DrugsFuture" /><ref name="Spreitzer" /><ref name="clinicaltrials" />

== Mechanism of action ==
Like other tetracyclines, incyclinide inhibits [[matrix metalloproteinases]].<ref name="DrugsFuture" />

== References ==
{{reflist|refs=
<ref name="Spreitzer">{{cite journal
 | author = H. Spreitzer
 | date = 2 July 2007
 | title = Neue Wirkstoffe - Incyclinid
 | journal = Ã–sterreichische Apothekerzeitung
 | issue = 14/2007
 | pages = 655
 | language = German
 }}</ref>
<ref name="DrugsFuture">{{cite journal
 | author = Viera, MH, Perez, OA, Berman, B
 | title = Incyclinide
 | journal = Drugs of the Future
 | volume = 32
 | issue = 3
 | pages = 209-214
 | url = http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1083308&p_IsPs=N
 }}</ref>
<ref name="Reuters">[https://www.reuters.com/article/companyNewsAndPR/idUSWEN127920070926 Reuters: CollaGenex says incyclinide ineffective for rosacea]</ref>
<ref name="clinicaltrials">[[ClinicalTrials.gov]]: [https://clinicaltrials.gov/ct2/results?term=Incyclinide&Search=Search Incyclinide]</ref>
}}



{{drug-stub}}

[[Category:Tetracycline antibiotics]]